Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma

Published:2017-08-10 Issue:8 Volume:18 Page:1736
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Bendtsen Mathias,Grimm Daniela,Bauer Johann,Wehland Markus,Wise Petra,Magnusson Nils,Infanger Manfred,Krüger Marcus

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

http://www.mdpi.com/1422-0067/18/8/1736/pdf

Reference57 articles.

1. Anti-Vascular Endothelial Growth Factor Therapy in Breast Cancer

2. Anti-VEGF-Induced Hypertension: a Review of Pathophysiology and Treatment Options

3. Anti-Angiogenic Drugs in the Treatment of Metastatic Renal Cell Carcinoma: Advances in Clinical Application

4. Effects and Side Effects of Using Sorafenib and Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma

5. Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Potential Mechanisms of Catechins in Tea for Anti-Hypertension: An Integration of Network Pharmacology, Molecular Docking, and Molecular Dynamics Simulation;Foods;2024-08-26

2. Hypertension in Cardio-Oncology Clinic: an update on etiology, assessment, and management;Cardio-Oncology;2023-12-12

3. Role of endothelin ETA receptors in the hypertension induced by the VEGFR-2 kinase inhibitors axitinib and lenvatinib in conscious freely-moving rats;Biochemical Pharmacology;2023-12

4. Impact of BMI on the Survival of Renal Cell Carcinoma Patients Treated with Targeted Therapy: A Systematic Review and Meta-Analysis;Nutrition and Cancer;2023-07-18

5. Cardiovascular effects of immunosuppression agents;Frontiers in Cardiovascular Medicine;2022-09-21